This page brings together the Agency's latest information on cancer. It lists:
This is a summary of the European public assessment report (EPAR) for Docetaxel Kabi. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its...
This is a summary of the European public assessment report (EPAR) for Sancuso. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
This is a summary of the European public assessment report (EPAR) for Pemetrexed Hospira. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions...
Onivyde is a cancer medicine that is used to treat a form of pancreatic cancer called metastatic adenocarcinoma of the pancreas. Metastatic means that the cancer has spread to other parts of the body...
This is a summary of the European public assessment report (EPAR) for Mvasi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is...
EMA has completed its assessment of the results of the ANNOUNCE study 1 and concluded that Lartruvo (olaratumab) with doxorubicin does not prolong the lives of patients with soft tissue cancer more than doxorubicin alone. The Agency is therefore...
Preliminary results from the ANNOUNCE study show that Lartruvo (olaratumab) in combination with doxorubicin is not more effective at prolonging the lives of patients with soft tissue cancer than doxorubicin alone.
Development of Kymriah and Yescarta supported through PRIME The European Medicines Agency (EMA) has recommended the first two marketing authorisations for chimeric antigen receptors (CAR) T-cells medicines in the European Union (EU). Kymriah (...
Nine medicines recommended for approval, including the first two CAR-T cell therapies in the EU The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including six orphan...
Preliminary assessment show no increase in frequency of known side effect The European Medicines Agency (EMA) is investigating the cancer medicine docetaxel following cases of neutropenic enterocolitis in patients in France, most of whom were being...
Review of liver cancer risk not conclusive and further studies are needed EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed that patients treated with medicines known as direct-acting antivirals for hepatitis C may be at risk of...
The innovation and biomarkers in cancer drug development (IBCD) 2018 event will embrace the full...
The third multi-stakeholder Paediatric Strategy Forum, jointly organised by EMA and ACCELERATE will...
The objective of this workshop is to facilitate the long-term follow up of CAR-T cell products in a...
Biological drivers that define cancer course across anatomical sites and histologies offer an...